NCT00385827 2014-08-20A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)Centocor, Inc.Phase 2 Terminated106 enrolled 13 charts
NCT00770848 2014-03-10AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate CancerAmgenPhase 1/2 Completed162 enrolled